Midazolam

# midazolam ## Overview - **Classification**: Benzodiazepine, short-acting. - **Mechanism**: Enhances the inhibitory effect of gamma-aminobutyric acid (GABA) on neuronal excitability, leading to CNS depression. ## Primary Indications 1. **Sedation for procedures**: Premedication or during short diagnostic/endoscopic procedures. 2. **Continuous sedation**: In critically ill, intubated, and mechanically ventilated patients. 3. **Treatment of status epilepticus**: Particularly refractory cases (IV) or acute seizure (buccal/nasal). ## Adult Dosing ### Standard Dosing **Procedural Sedation/Anxiolysis (IV)** - **Dose**: **0.02-0.1 mg/kg** - **Frequency**: Titrate slowly over 2-3 minutes; wait at least 2 minutes for full effect. - **Route**: Intravenous (IV) - **Maximum**: Single dose max **2.5 mg**. Total max **5-10 mg** (for healthy adults <60 years). - **Special Considerations**: Start with **1-2 mg** for initial dose. **Continuous Sedation (IV Infusion)** - **Dose**: **0.02-0.1 mg/kg/hr** (initial bolus **0.01-0.05 mg/kg** may precede infusion). - **Frequency**: Continuous infusion. - **Route**: Intravenous (IV) - **Maximum**: **0.4 mg/kg/hr**. Titrate to desired level of sedation. **Status Epilepticus (Refractory, IV)** - **Dose**: **0.1-0.2 mg/kg** IV bolus - **Frequency**: May be followed by continuous infusion as above. - **Route**: Intravenous (IV) - **Maximum**: **10 mg** per single bolus. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment recommended for single dose. Monitor for prolonged effects with CrCl <30 mL/min, especially with continuous infusions. - **Hepatic Impairment**: Reduced clearance, prolonged half-life. Decrease dose by **25-50%** and titrate carefully. - **Elderly Patients (>60 years)**: Start with lower doses (**0.01-0.03 mg/kg IV** for procedural sedation, max **1.5 mg** initial dose). Titrate slowly; increased sensitivity and risk of respiratory depression. ## Pediatric Dosing ### Neonates (0-28 days) - **Indication**: Sedation for intubation or prolonged sedation. - **Dose**: Loading dose **0.05-0.15 mg/kg IV** over several minutes. - **Frequency**: Follow with continuous infusion of **0.01-0.06 mg/kg/hr**. - **Route**: Intravenous (IV) - **Maximum**: Infusion max **0.06 mg/kg/hr**. - **Special Notes**: Use preservative-free formulation. Neonates have prolonged half-life; higher risk of apnea/hypotension. ### Infants (1-12 months) - **Indication**: Procedural sedation, acute seizure. - **Dose (IV)**: Loading dose **0.05-0.1 mg/kg IV** over 2-3 min. Max single dose **0.2 mg/kg** (up to **6 mg** total). - **Dose (Nasal/Buccal for Acute Seizure)**: **0.2-0.5 mg/kg**. - **Frequency**: IV: Titrate as needed. Nasal/Buccal: Single dose for acute seizure. - **Route**: Intravenous (IV), Intranasal (IN), Buccal (BC) - **Maximum**: IV single dose **6 mg**. Nasal/Buccal **10 mg**. ### Children (1-12 years) - **Indication**: Procedural sedation, acute seizure, status epilepticus. - **Dose (IV)**: Loading dose **0.05-0.1 mg/kg IV** over 2-3 min. - **Frequency**: Titrate to desired effect; total dose max **0.2 mg/kg** (up to **6 mg** total). - **Route**: Intravenous (IV) - **Dose (Nasal/Buccal for Acute Seizure)**: **0.2-0.5 mg/kg**. - **Frequency**: Single dose for acute seizure. - **Maximum**: IV total dose **6 mg**. Nasal/Buccal **10 mg**. - **Special Considerations**: Oral formulations (syrup) can be used for premedication (**0.25-0.5 mg/kg** up to **20 mg**) 30-45 min pre-procedure. ### Adolescents (13-18 years) - **Dose**: Generally follows **adult dosing** guidelines. - **Frequency**: Titrate to desired effect. - **Maximum**: Adult max doses apply. ## Safety Information ### Contraindications - **Absolute**: Acute narrow-angle glaucoma. - **Absolute**: Severe respiratory depression, acute respiratory insufficiency. - **Absolute**: Hypersensitivity to midazolam or other benzodiazepines. - **Relative**: Myasthenia gravis (use with extreme caution). ### Common Adverse Effects - **Very Common (>10%)**: Decreased respiratory rate, apnea, injection site reactions. - **Common (1-10%)**: Hypotension, drowsiness, headache, nausea, vomiting. - **Serious but Rare**: Paradoxical reactions (agitation, involuntary movements), seizures (withdrawal), cardiac arrest. ### Key Drug Interactions - **Opioids/Other CNS Depressants (e.g., alcohol, sedatives)**: Potentiated respiratory depression and sedation. Requires reduced midazolam dose. - **Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit juice)**: Markedly increased midazolam levels and prolonged effects. Avoid concomitant use or significantly reduce midazolam dose. - **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin)**: Decreased midazolam levels and reduced efficacy. May require increased midazolam dose. ## Monitoring & Follow-up - **Before Treatment**: Assess respiratory status, vital signs, level of consciousness, and medication history. - **During Treatment**: Continuously monitor oxygen saturation, heart rate, blood pressure, respiratory rate, and level of consciousness (Ramsay or RASS scale). - **Clinical Signs**: Watch for excessive sedation, paradoxical reactions, respiratory depression, or apnea. Have resuscitation equipment readily available. ## Clinical Pearls - 💡 **Rapid Onset**: IV midazolam has a rapid onset (1-5 minutes) and short duration of action (20-60 minutes). - 💡 **Titrate Slowly**: Always titrate slowly to effect, especially in elderly or debilitated patients, to minimize risk of respiratory depression. - 💡 **Antidote Available**: Flumazenil is a benzodiazepine antagonist that can reverse midazolam's effects if severe oversedation occurs. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.